Basic Information:Size of the oncology drug market in Pakistan = 200-250 crore According to IMS, about one-third of the $1.2-billion pharma market in Pakistan is imported.Licensed pharma companies in Pakistan = 400 (Including MNCs.)Licensed MNCs = 30MNCs market Share: 53% Other InformationIncidence of cancer in Pakistan is 730,956/annum

Cancer %Breast Cancer = 38.5%Lung Cancer = 18% of all casesLymphomas - Hodgkin's disease or Non-Hodgkin's lymphomas = 13%Prostate cancer = 8%Leukemia = 6%Bowel cancer = 8%Bladder cancer = 5%Head, Face and Neck cancers (lip, mouth or throat) = 5%In Pakistani women the 7 most common cancers are:Breast cancer = 38.5% of all casesCervical cancer - cancer of the neck of the womb = 6%Lymphomas - Hodgkins disease or Non-Hodgkin's lymphoma = 6%Ovarian cancer = 6%Leukemia = 5%Bowel cancer = 4%Head, Face and Neck cancers (lip, mouth or throat) = 4%

Breast Cancer:Detected in young girls and onwards (52% women population in Pakistan)Breast cancer = 38.5% of all female cancers in Pakistan (death rate ratio 1/9)

Liver Cancer:Liver Cancer = 6 per 100,000 males and 4 per 100,000 females. Liver Cancer survival rate = 3-5% only.Detected in 40s & 50s (40% of the total population of Pakistan)Hoora Pharmaceutical: What should be our Vision? To make difference in humans life every second.What should be our mission statement? Safe Humanity, live healthy and longer. Pharma Direction Setting 1- Selection of product2- To make feasibility report 3- To make financial viability (setting targets and breakeven) 4- To launch at most 3 oncology product within 6 months to 1 year Deadline April 20155- To also acquire medical devices in the disease where Hoora is going to promote its business.6- To set the structure of this group before launching the product?7- To conduct training, availability of product and distributor appointment8- Launching of the product9- Routine Marketing Top 10 Selling Brand in US BrandGenericMarket In USClinical UsageCompetitorMin vs Max PKR TPCompany

RituxanRituximab $3 billionAdvanced follicular lymphoma, and breast cancer1 DCMab Thera100 mg = 39,100500 mg = 96,900Mabion Ph I

AvastinBevacizumab$2.66 billionBrain tumors,Breast cancer,Lung cancer,Metastatic colorectal cancer.1 DC100mg=24480400mg=97325Mabion Ph III

HerceptinTrastuzumab$1.66 billionMetastatic breast cancer1 DC440mg=110500Mabion Ph I

GleevecImatinib$1.51 billionChronic myeloid leukemia and Gastrointestinal stromal tumour.1 DC100mg=169575400mg=119000

EloxatinOxaliplatin$1.2 billionMetastatic colorectal cancer9 DC100mg= 13600 vs 17000ILDONG

AlimtaPemetrexed$1.04 billionMesothelioma,Non-small cell lung carcinoma.2 DC100mg=16065500mg=59500

ErbituxCetuximab$703.3 millionHead, neck, and colorectal cancer.1 DC100mg=24225Mabion Ph III

VelcadeBortezomib$692.7 millionmultiple myeloma

XelodaCapicitabine$647.6 millionBreast cancer, Metastatic,Metastatic colorectal cancer.1 DC500mg=21250ILDONG

TarcevaErlotinib$564.2 millionMetastatic lung cancer and Metastatic pancreatic cancer.1DC25mg100mg150mg

10 promising late-stage cancer drugs1. Carfilzomib - multiple myeloma2. Crizotinib (PF-02341066) - lung cancer3. GDC-0449 (vismodegib) - basal cell carcinoma4. OncoVex - advanced melanoma5. PLX4032 (RG7204) - melanoma6. Ponatinib - leukemia 7. SGN-35 (brentuximab vedotin) - Hodgkin's lymphoma, anaplastic large cell lymphomas8. Tivozanib (AV-951) - advanced renal cell carcinoma 9. T-DM1 (Trastuzumab-DM1) - breast cancer10. XL184 (cabozantinib) - prostate cancer